The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation
Authors:
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 149 (1) , e1-e6
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pathology of Acute and Chronic Coronary Stenting in HumansCirculation, 1999
- Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injuryJournal of Human Hypertension, 1999
- Neointimal Tissue Response at Sites of Coronary Stenting in HumansCirculation, 1998
- Upregulation of Angiotensin-Converting Enzyme During the Healing Process After Injury at the Site of Percutaneous Transluminal Coronary Angioplasty in HumansCirculation, 1997
- Patterns and Mechanisms of In-Stent RestenosisCirculation, 1996
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Lesion-to-lesion independence of restenosis after treatment by conventional angioplasty, stenting, or directional atherectomy. Validation of lesion-based restenosis analysis.Circulation, 1993
- A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapiesJACC, 1991
- Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteriesLife Sciences, 1991